These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 11375890)

  • 1. Inhibition of HIF-1- and wild-type p53-stimulated transcription by codon Arg175 p53 mutants with selective loss of functions.
    Blagosklonny MV; Giannakakou P; Romanova LY; Ryan KM; Vousden KH; Fojo T
    Carcinogenesis; 2001 Jun; 22(6):861-7. PubMed ID: 11375890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperinducibility of hypoxia-responsive genes without p53/p21-dependent checkpoint in aggressive prostate cancer.
    Salnikow K; Costa M; Figg WD; Blagosklonny MV
    Cancer Res; 2000 Oct; 60(20):5630-4. PubMed ID: 11059752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
    Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
    Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of wild-type p53 activity by mutant p53 R273H depends on the p53 responsive element (p53RE). A comparative study between the p53REs of the MDM2, WAFI/Cip1 and Bax genes in the lung cancer environment. WAFI/Cip1 = WAF1/Cip1.
    Zacharatos PV; Gorgoulis VG; Kotsinas A; Manolis EN; Liloglou T; Rassidakis AN; Kanavaros P; Field JD; Halazonetis T; Kittas C
    Anticancer Res; 1999; 19(1A):579-87. PubMed ID: 10226602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct promoter elements mediate the co-operative effect of Brn-3a and p53 on the p21 promoter and their antagonism on the Bax promoter.
    Perez-Sanchez C; Budhram-Mahadeo VS; Latchman DS
    Nucleic Acids Res; 2002 Nov; 30(22):4872-80. PubMed ID: 12433990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 inhibits hypoxia-inducible factor-stimulated transcription.
    Blagosklonny MV; An WG; Romanova LY; Trepel J; Fojo T; Neckers L
    J Biol Chem; 1998 May; 273(20):11995-8. PubMed ID: 9575138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A transcriptional activation function of p53 is dispensable for and inhibitory of its apoptotic function.
    Kokontis JM; Wagner AJ; O'Leary M; Liao S; Hay N
    Oncogene; 2001 Feb; 20(6):659-68. PubMed ID: 11313999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of apoptosis by the p53-273L (Arg --> Leu) mutant in HSC3 cells without transactivation of p21Waf1/Cip1/Sdi1 and bax.
    Kaneuchi M; Yamashita T; Shindoh M; Segawa K; Takahashi S; Furuta I; Fujimoto S; Fujinaga K
    Mol Carcinog; 1999 Sep; 26(1):44-52. PubMed ID: 10487521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The chimeric E2A-HLF transcription factor abrogates p53-induced apoptosis in myeloid leukemia cells.
    Altura RA; Inukai T; Ashmun RA; Zambetti GP; Roussel MF; Look AT
    Blood; 1998 Aug; 92(4):1397-405. PubMed ID: 9694729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines.
    Aurelio ON; Kong XT; Gupta S; Stanbridge EJ
    Mol Cell Biol; 2000 Feb; 20(3):770-8. PubMed ID: 10629033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel p53 mutant retained functional activity in lung carcinomas.
    Ko JL; Chiao MC; Chang SL; Lin P; Lin JC; Sheu GT; Lee H
    DNA Repair (Amst); 2002 Sep; 1(9):755-62. PubMed ID: 12509279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
    Inga A; Resnick MA
    Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germ-line mutation: evidence for a precursor lesion.
    Fulci G; Ishii N; Maurici D; Gernert KM; Hainaut P; Kaur B; Van Meir EG
    Cancer Res; 2002 May; 62(10):2897-905. PubMed ID: 12019170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells.
    Davis P; Bazar K; Huper G; Lozano G; Marks J; Iglehart JD
    Oncogene; 1996 Sep; 13(6):1315-22. PubMed ID: 8808706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of differential activation of target gene promoters by p53 hinge domain mutants with impaired apoptotic function.
    Kong XT; Gao H; Stanbridge EJ
    J Biol Chem; 2001 Aug; 276(35):32990-3000. PubMed ID: 11395510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest.
    Ryan KM; Vousden KH
    Mol Cell Biol; 1998 Jul; 18(7):3692-8. PubMed ID: 9632751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
    Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant p53 proteins behave in a dominant, negative fashion in vivo.
    Hachiya M; Chumakov A; Miller CW; Akashi M; Said J; Koeffler HP
    Anticancer Res; 1994; 14(5A):1853-9. PubMed ID: 7847818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective transcription of p53 target genes by zinc finger-p53 DNA binding domain chimeras.
    Falke D; Fisher MH; Juliano RL
    Biochim Biophys Acta; 2004 Nov; 1681(1):15-27. PubMed ID: 15566940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.
    Willis A; Jung EJ; Wakefield T; Chen X
    Oncogene; 2004 Mar; 23(13):2330-8. PubMed ID: 14743206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.